Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAVs-loaded autologous leukemic cells + dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- University of Miami
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
This experimental combination immunotherapy, developed by Juan C. Ramos, MD at the University of Miami, is designed to treat aggressive relapsed or refractory leukemias. The therapy consists of two primary biological components: autologous leukemic cells that have been ultraviolet (UV)-irradiated and loaded with STING-dependent activators (STAVs), and a vaccine composed of mature autologous dendritic cells. The STAVs serve as potent adjuvants that trigger the Stimulator of Interferon Genes (STING) pathway within the leukemic cells, enhancing their immunogenicity. When these loaded, inactivated cells are administered alongside mature dendritic cells, the dendritic cells process and present leukemia-specific antigens to the patient's T cells. This process is intended to overcome immune evasion and stimulate a robust, systemic anti-leukemic immune response specifically targeting acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and adult T-cell leukemia/lymphoma (ATL).
- Other names
- STAVs and Stimulated Dendritic CellsSTING-dependent Activators and Dendritic Cell VaccineSTING-dependent Activators (STAVs) Loaded Autologous Leukemic Cells and Dendritic Cell Vaccine
Beyond the preview
Go deeper on STAVs-loaded autologous leukemic cells + dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAVs-loaded autologous leukemic cells + dendritic cell vaccine.